REFERENCES
- Dhillon S. Carotegrast methyl: First approval. Drugs .
2022;82(9):1011-6. doi: 10.1007/s40265-022-01732-0.
- Yoshimura N, Watanabe M, Motoya S, et al. Safety and efficacy of
AJM300, an oral antagonist of α4 integrin, in induction therapy for
patients with active ulcerative colitis. Gastroenterology .
2015;149(7):1775-83.e2. doi: 10.1053/j.gastro.2015.08.044.
- Matsuoka K, Watanabe M, Ohmori T, et al. AJM300 (carotegrast methyl),
an oral antagonist of α4-integrin, as induction therapy for patients
with moderately active ulcerative colitis: a multicentre, randomised,
double-blind, placebo-controlled, phase 3 study. Lancet
Gastroenterol Hepatol . 2022;7(7):648-57. doi:
10.1016/S2468-1253(22)00022-X.
- Bloomgren G, Richman S, Hotermans C, et al. Risk of
natalizumab-associated progressive multifocal leukoencephalopathy.N Engl J Med . 2012;366(20):1870-80. doi: 10.1056/NEJMoa1107829.
- McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring
of natalizumab-associated progressive multifocal leukoencephalopathy
risk: recommendations from an expert group. J Neurol Neurosurg
Psychiatry . 2016;87(2):117-25. doi: 10.1136/jnnp-2015-311100.
- Williamson EML, Berger JR. Diagnosis and treatment of progressive
multifocal leukoencephalopathy associated with multiple sclerosis
therapies. Neurotherapeutics . 2017;14(4):961-73. doi:
10.1007/s13311-017-0570-7.
- Package insert of Carogra® Tablets.
https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/111890_2399018F1024_1_02Japanese.
Accessed August 20, 2023.
- Fukase H, Kajioka T, Oikawa I, Ikeda N, Furuie H. Food effect on a
single high dose of carotegrast methyl, an oral antagonist of
α4-integrin, in healthy male subjects: a randomised,
placebo-controlled, double-blind study. Clin Drug Investig .
2020;40(3):237-47. doi: 10.1007/s40261-019-00879-1.
- Fukase H, Kajioka T, Oikawa I, Ikeda N, Furuie H. AJM300, a novel oral
antagonist of α4-integrin, sustains an increase in circulating
lymphocytes: A randomised controlled trial in healthy male subjects.Br J Clin Pharmacol. 2020;86(3):591-600. doi:
10.1111/bcp.14151.
- Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative
colitis. Lancet . 2012;380(9853):1606-19. doi:
10.1016/S0140-6736(12)60150-0.
- Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology,
diagnosis, and management. Mayo Clin Proc . 2014;89(11):1553-63.
doi: 10.1016/j.mayocp.2014.07.002.
- Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF.
Ulcerative colitis. Lancet . 2017;389(10080):1756-70. doi:
10.1016/S0140-6736(16)32126-2.
- Nigam SK. What do drug transporters really do? Nat Rev Drug
Discov . 2015;14(1):29-44. doi: 10.1038/nrd4461.
- Kalliokoski A, Niemi M. Impact of OATP transporters on
pharmacokinetics. Br J Pharmacol . 2009;158(3):693-705. doi:
10.1111/j.1476-5381.2009.00430.x.
- Ministry of Health, Labour and Welfare, Guideline on drug interaction
for drug development and appropriate provision of information.
https://www.pmda.go.jp/files/000228122.pdf. Accessed April 8, 2023.
- Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal
P-glycoprotein (mdr1) in interpatient variation in the oral
bioavailability of cyclosporine. Clin Pharmacol Ther .
1997;62(3):248-60. doi: 10.1016/S0009-9236(97)90027-8.
- Kambayashi R, Goto A, Izumi-Nakaseko H, et al. Appraisal of ICH
E14/S7B Q&As adopted in February 2022 using thorough QT/QTc study
data for α4-integrin antagonist carotegrast methyl in Japanese healthy
subjects. J Pharmacol Sci . 2022;150(3):191-9. doi:
10.1016/j.jphs.2022.08.007.
- The package insert of Rifampicin Capsules.
https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/430574_6164001M1216_1_15.
Japanese. Accessed 18 June, 2023.
- Shumaker RC, Aluri J, Fan J, Martinez G, Thompson GA, Ren M. Effect of
rifampicin on the pharmacokinetics of lenvatinib in healthy adults.Clin Drug Investig . 2014;34(9):651-9. doi:
10.1007/s40261-014-0217-y.
- Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Evaluation of rifampin’s
transporter inhibitory and CYP3A inductive effects on the
pharmacokinetics of venetoclax, a BCL-2 inhibitor: results of a
single- and multiple-dose study. J Clin Pharmacol .
2016;56(11):1335-43. doi: 10.1002/jcph.730.